title: Oleic Acid Coated Gelatin Nanoparticles Impregnated Gel for Sustained Delivery of Zaltoprofen: Formulation and Textural Characterization.
abstract: OBJECTIVE
  In the present study, we have formulated zaltoprofen loaded, surface decorated, biodegradable gelatin nanogel and evaluated its texture characterization.
  
  
  METHODS
  The method used to prepare gelatin nanoparticles (GNP) was 'two step desolvation' and its surface decoration was performed with oleic acid (OA). The GNP was optimized by DOE software. Nanogels were evaluated for particle size entrapment efficiency, texture properties, SEM, in-vitro, ex-vivo drug release studies, in-vitro characterization, stability and in vivo evaluation of nanogel for anti-inflammatory activity was carried out by carrageenan induced rat paw edema method as an anti-inflammatory experimental model.
  
  
  RESULTS
  The formulated GNP with particle size and entrapment efficiency of optimized batch was found to be 247.1 nm and 76.21% respectively. The SEM of GNP shows smooth and spherical shape. In-vitro and Ex-vivo drug release shows that there was 69.47% and 78.59% drug released within 48 hrs. It follows Ritger peppas model, which indicates sustained drug release. The good texture properties of nanogel were observed from texture analysis graphs.In vivo studies of our formulation give significant results compared to the marketed nanogel. Stability data revealed stability of nanogel formulation up to 3 months.
  
  
  CONCLUSIONS
  The present approach can provide us promising results of the sustained analgesic activity and the stability of drug within the GNP.
authors.affiliation: R.C. Patel College of Pharmaceutical Education and Research, Shirpur, India 425405.
authors.forename: Savita
authors.initials: S
authors.lastname: Pawar
authors.affiliation: Sanjivani College of Pharmaceutical Education and Research, Kopargaon, India 423603.
authors.forename: Vishal
authors.initials: V
authors.lastname: Pande
keywords: CT3 Texture analyzer; Gelatin nanoparticles; Glutaradehyde; Oleic acid; Zaltoprofen
references.citation: Neurosci Lett. 2006 Apr 24;397(3):249-53
references.pmid: 16406342
references.citation: J Biomater Sci Polym Ed. 2011;22(4-6):753-71
references.pmid: 20566056
references.citation: J Control Release. 2005 Dec 5;109(1-3):256-74
references.pmid: 16266768
references.citation: Drug Dev Ind Pharm. 2013 Feb;39(2):310-20
references.pmid: 23323873
references.citation: Eur J Pharm Biopharm. 2008 Jun;69(2):622-32
references.pmid: 18248972
references.citation: Drug Dev Ind Pharm. 2013 Nov;39(11):1774-82
references.pmid: 23136990
references.citation: Nanomedicine. 2006 Mar;2(1):8-21
references.pmid: 17292111
references.citation: Int J Pharm. 2010 Nov 15;400(1-2):176-82
references.pmid: 20727392
references.citation: J Control Release. 2003 Apr 14;89(1):127-40
references.pmid: 12695068
references.citation: Biomaterials. 2012 Feb;33(5):1607-17
references.pmid: 22118820
references.citation: J Control Release. 2011 Jan 20;149(2):159-67
references.pmid: 20950659
references.citation: Neurosci Res. 2006 Apr;54(4):288-94
references.pmid: 16473424
references.citation: J Control Release. 2005 Feb 16;102(3):643-56
references.pmid: 15681086
references.citation: Adv Pharm Bull. 2014;4(2):121-30
references.pmid: 24511475
references.citation: J Microencapsul. 2000 Mar-Apr;17(2):187-93
references.pmid: 10738694
references.citation: Adv Drug Deliv Rev. 2012 Jun 15;64(9):836-51
references.pmid: 22342438
references.citation: J Microencapsul. 2012;29(5):497-504
references.pmid: 22769722
references.citation: Mod Rheumatol. 2003 Jun;13(2):143-52
references.pmid: 24387174
references.citation: Curr Drug Deliv. 2009 Jan;6(1):93-100
references.pmid: 19418961
references.citation: Nanomedicine. 2008 Sep;4(3):252-61
references.pmid: 18502187
references.citation: Eur J Pharm Biopharm. 2004 Mar;57(2):251-61
references.pmid: 15018982